AB Science: Masitinib in Mastocytosis - Summary of Web

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AB Science: Masitinib in Mastocytosis - Summary of Web Conference

PARIS, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Paris, 10 November 2014, 8.30 am

Masitinib in Mastocytosis - Summary of Web Conference

In 2015 AB Science will have readout of phase 3 in
 severe systemic mastocytosis, which is non futile near completion

AB Science will expand the mast cell franchise by initiating
phase 3 studies in a common disease called MCAS and in pediatric mastocytosis

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), provides a summary of the key points of the web conference held on 7 th November 2014 on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.

The current phase 3 study in mastocytosis has been assessed in September 2014 as non futile by the Independent Data Safety and Monitoring Committee at a time when the study was close to completion. A futility analysis tests the inability of a clinical study to achieve its efficacy objective. The phase 3 read-out in severe systemic mastocytosis is expected anytime in 2015. The target population in adult patients with severe systemic mastocytosis is estimated at 10,000 in the USA and in the EU. In case of positive results, filing at both FDA and EMA would be pursued.

In order to expand the mast cell franchise that started with severe systemic mastocytosis in adults, AB Science has decided to initiate in 2015 two new phase 3 studies in Mast Cell Activation Syndrome (MCAS) and in pediatric mastocytosis.

Mastocytosis in children gives urticaria pigmentosa and is primarily due to mutations of c-Kit that are efficiently inhibited by masitinib. The target population in children with mastocytosis is estimated at 20,000 in the USA and in the EU.

MCAS targets a much broader population than mastocytosis. MCAS is a common disease caused by activation of mast cells and associated with the same symptoms as in mastocytosis, such as chronic fatigue, pain, depression, diarrhea, irritable bowel, pruritus, flush and anaphylaxis, but it affects around 5 to 10% of general population. MCAS could include part of diseases such as multiple sclerosis, Crohn's disease, inflammatory bowel disease, Duchene muscular dystrophy, chronic fatigue syndrome, when such diseases exhibit clear signs of mast cell hyperactivity (such as increased tryptase in blood, increased histamine in urine, dermographism). Because masitinib has been designed to be a potent inhibitor of mast cell activation (through its action against c-Kit, Lyn and Fyn tyrosine kinases), it is a suitable drug candidate in MCAS. As for systemic mastocytosis, MCAS symptoms can be mild, moderate, or severe. The proportion of severe forms where masitinib could be developed is unknown but the prevalence of severe forms of MCAS is estimated by experts to be up to a 100 times larger than in mastocytosis on the basis of their own clinical experience. In MCAS, the mutations of c-Kit or other genes driving the activation of mast cells are unknown but different from the ones driving mastocytosis. The phase 3 clinical study that AB Science will launch in 2015 will be used to identify those mutations.

The safety database of masitinib is adequate to support registration in mastocytosis, especially in the context of an orphan designation. Indeed, in case of filing, the safety database presented would include 250 patient enrolled in mastocytosis studies, and would exceed guideline requirements for drugs intended for long-term treatment in non-life threatening disease, with over 1,500 patients exposed to masitinib, including over 600 patients (versus 300 required) treated for 6 months and over 300 patients (versus 100 required) treated for 12 months.

Potential objections on Manufacturing or Preclinical data have been resolved through the applications filed at EMA for GIST and pancreatic cancer.

AB Science is ideally positioned to commercialize masitinib in mastocytosis in case of registration. A network of physician specialists is already structured in Europe, with ECNM (like in GIST). Similarly a network of patients is already structured through national patient associations in the main countries, and founders of AB Science are also founders of the French patient association AFIRMM with over 2,500 patients identified. AB Science developed close relationship with patients association and Key Opinion Leaders in the past 10 years. No license has been granted so far and AB Science retains 100% of masitinib rights.

Intellectual Property for masitinib is secured in mastocytosis until 2028, potentially until 2031, and potentially until 2034 for MCAS. Patent protection on composition of matter for masitinib has been filed and delivered and will be extended until 2028 through patent tem extension (PTE). A further protection until 2028 has been achieved through a synthesis process patent already granted. In addition, further protection could be obtained until 2031 for the treatment of severe systemic mastocytosis and until 2034 for treatment of MCAS, respectively through patents filed in 2011 after phase 2 results in mastocytosis and in 2014 for MCAS. A 10 year exclusivity period can be granted from the date of registration since masitinib has been granted orphan drug status in mastocytosis by both FDA and EMA. A further 6 months exclusivity can be granted in case on implementation of a pediatric investigation plan, as will be the case for masitinib in mastocytosis.

About masitinib
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in human and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

*   *   *

AB Science - Financial Communication & Media Relations
investors@ab-science.com

AB Science EN http://hugin.info/155655/R/1870072/657631.pdf

HUG#1870072

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 93

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 100

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 181

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 27

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 204

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 26

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 9

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 59

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 267

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 74

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading

Top 5 Most Recently Viewed Articles

Ping An Healthcare Delivers Impressive Growth in Interim Results

Updated Category News Views 186

Impressive Interim Results from Ping An Healthcare Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) has announced robust interim results for the six-month period ending June 30, showing significant progress following its return to profitability. Throughout this period, the Company has demonstrated strong revenue growth and a notable...

Continue Reading
Market Insights: Trends in Precious Metals and Sector Performance

Updated Category News Views 201

Understanding Market Dynamics and Precious Metals The current landscape of Wall Street might appear quiet at first glance, especially during the lull between holidays. However, beneath this surface lies a surge of activity, particularly in the realm of precious metals. Investors are keenly observing the uptick in volatility, specifically concerning silver and other key...

Continue Reading
Discover the Most Popular Pet Breeds of 2025: Insights and Trends

Updated Category News Views 409

Understanding the 2025 Top Pet Breeds The bond between pets and their owners often mirrors our own personalities and values. Recent insights reveal that 8 out of 10 pet parents believe a dog breed reflects a person's character. Across different breeds, qualities such as friendliness, sociability, and playfulness top the charts when pet parents make their choices. The...

Continue Reading
Amicus Therapeutics Engages Investors at Key Conferences Soon

Updated Category News Views 129

Amicus Therapeutics to Present at Upcoming Investor Conferences Amicus Therapeutics (Nasdaq: FOLD), a dedicated player in the biotechnology landscape, has announced its forthcoming participation in significant investor conferences this September, showcasing its unwavering commitment to fostering investor relations. Details of the Upcoming Presentations The company has...

Continue Reading
Understanding RPM Intl's P/E Ratio in Market Context

Updated Category News Views 206

Understanding RPM Intl's Stock Performance Currently, RPM Intl Inc. (NYSE: RPM) is experiencing a share price of $123.50, reflecting a modest increase of 0.36%. This uptick is notable amidst a turbulent month, where the stock has decreased by 11.21%. However, when we look back over the past year, we see a positive trend, with the stock appreciating by 16.26%. Investors...

Continue Reading